Follow The Filings

PTGX position history

The shares of Protagonist Therapeutics (PTGX) that Duquesne Family Office LLC reported in each quarter’s 13F.

Equity, COM

Shares held by quarter

New Add Reduce Exit

  1. 2025 Q3: 159,700 shares, $11M, 0.26% of portfolio, New
  2. 2025 Q4: 159,700 shares, $14M, 0.31% of portfolio
  3. 2026 Q1: 159,700 shares, $17M, 0.50% of portfolio
  4. 2026 Q2: 208,900 shares, $26M, 0.49% of portfolio, Add +30.8%
  5. 2026 Q3: not held, Exit
Holdings date Value % of holdings Shares Filing date All 13F holders